Neurocognitive testing in a murine model of mucopolysaccharidosis type IIIA

Kleopatra Pericleous1,2, Chantelle McIntyre1, Maria Fuller1,2,3

  • 1Genetics and Molecular Pathology, SA Pathology at Women's and Children's Hospital, 72 King William Road, North Adelaide 5006, Australia.

Insights

Behavioral tests reliably assess Mucopolysaccharidosis type IIIA (MPS IIIA) progression in mice. Water maze, gait, burrowing, and nest building show deficits mirroring human neurodegeneration, unlike other tests.

Area of Science:

  • Neuroscience
  • Genetics
  • Biochemistry

Background:

  • Mucopolysaccharidosis type IIIA (MPS IIIA) is a neurodegenerative disorder caused by heparan sulfate accumulation.
  • Assessing neurological function in MPS IIIA mouse models is crucial for treatment evaluation.
  • Existing behavioral tests may not accurately reflect disease progression.

Purpose of the Study:

  • To evaluate the reliability of various behavioral tests for assessing MPS IIIA mouse model disease progression.
  • To identify suitable behavioral endpoints for preclinical studies of MPS IIIA.

Main Methods:

  • Comparison of MPS IIIA mice and wild-type (WT) littermates.
  • Assessment using water cross-maze, hind-limb gait analysis, burrowing, nest building, open field, and three-chamber sociability tests.
  • Correlation of behavioral changes with heparan sulfate accumulation in the brain.

Main Results:

  • MPS IIIA mice showed memory deficits (water cross-maze) and locomotor impairment (hind-limb gait) at later disease stages.
  • Declined wellbeing was observed via burrowing and nest building in MPS IIIA mice.
  • Heparan sulfate accumulation preceded measurable behavioral decline, suggesting a threshold effect.
  • Open field and sociability tests yielded inconsistent results and were deemed unreliable.

Conclusions:

  • Water cross-maze, hind-limb gait, nest building, and burrowing are reliable assessments for MPS IIIA mouse models.
  • These validated tests effectively mimic human MPS IIIA disease progression.
  • Reliable behavioral endpoints are essential for preclinical treatment evaluation in MPS IIIA.

Related Concept Videos